Cargando…

p53 as a biomarker and potential target in gastrointestinal stromal tumors

KIT and PDGFRA play a major role in the oncogenic process in gastrointestinal stroma tumors (GIST) and small molecules have been employed with great success to target the KIT and PDGFRA pathways in this cancer. However, approximately 10% of patients with GIST are resistant to current targeted drug t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chiao-En, Chen, Chiao-Ping, Huang, Wen-Kuan, Pan, Yi-Ru, Aptullahoglu, Erhan, Yeh, Chun-Nan, Lunec, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372431/ https://www.ncbi.nlm.nih.gov/pubmed/35965531 http://dx.doi.org/10.3389/fonc.2022.872202

Ejemplares similares

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
por: Wu, Chiao-En, et al.
Publicado: (2020)

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells
por: Wu, Chiao-En, et al.
Publicado: (2021)

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View
por: Wu, Chiao-En, et al.
Publicado: (2019)

A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters
por: Chang, Yau-Ren, et al.
Publicado: (2021)

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
por: Aptullahoglu, Erhan, et al.
Publicado: (2023)

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
por: Ciardullo, Carmela, et al.
Publicado: (2019)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study
por: Yeh, Chun-Nan, et al.
Publicado: (2021)

ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner
por: Pan, Yi-Ru, et al.
Publicado: (2020)

Gastrointestinal Stromal Tumors: Deception to the Eyesight
por: Haddad, Fady G., et al.
Publicado: (2017)

Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor
por: Chen, Yuhong, et al.
Publicado: (2023)

Overexpressed transferrin receptor implied poor prognosis and relapse in gastrointestinal stromal tumors
por: Zhuang, Chun, et al.
Publicado: (2023)

TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
por: Wu, Chiao-En, et al.
Publicado: (2019)

Advances and Challenges on Management of Gastrointestinal Stromal Tumors
por: Mei, Lin, et al.
Publicado: (2018)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma
por: Pan, Yi-Ru, et al.
Publicado: (2022)

Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors
por: Xue, Anwei, et al.
Publicado: (2022)

Imatinib Regulates miR-483-3p and Mitochondrial Respiratory Complexes in Gastrointestinal Stromal Tumors
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia
por: Aptullahoglu, Erhan, et al.
Publicado: (2023)

p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors
por: Henze, Joern, et al.
Publicado: (2012)

Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies
por: Ko, Tun Kiat, et al.
Publicado: (2022)

Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
por: Chiang, Ming-Fu, et al.
Publicado: (2013)

Succinate Dehydrogenase Deficiency in Pediatric and Adult Gastrointestinal Stromal Tumors
por: Belinsky, Martin G., et al.
Publicado: (2013)

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
por: Sun, Yingchao, et al.
Publicado: (2022)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Functional Genetic Variant of Long Pentraxin 3 Gene Is Associated With Clinical Aspects of Oral Cancer in Male Patients
por: Yeh, Chia-Ming, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model
por: Pan, Yi-Ru, et al.
Publicado: (2020)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
por: Hu, Xiangchen, et al.
Publicado: (2022)

Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial
por: Wu, Chiao-En, et al.
Publicado: (2021)

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib
por: Lei, Tianxiang, et al.
Publicado: (2021)

SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor
por: Pantaleo, Maria A., et al.
Publicado: (2022)

MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors
por: Mao, Haijia, et al.
Publicado: (2021)

Editorial: Improving post-surgical outcomes for patients with primary gastrointestinal stromal tumors
por: Koniaris, Leonidas G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kflrcd039npr7rd1n37oqp3oje